The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 7 March 2006, www.theannals.com, DOI 10.1345/aph.1G389.
 The Annals of Pharmacotherapy: Vol. 40, No. 5, pp. 909-916. DOI 10.1345/aph.1G389
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chavez, B.
Right arrow Articles by Rey, J. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chavez, B.
Right arrow Articles by Rey, J. A

PSYCHIATRY

Role of Risperidone in Children with Autism Spectrum Disorder

Benjamin Chavez, PharmD

Clinical Assistant Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ

Mapy Chavez-Brown, PhD

Assistant Professor, Education Department, Wagner College, Staten Island, NY

Jose A Rey, PharmD

Associate Professor, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, FL

Reprints: Dr. Chavez, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Way, Piscataway, NJ 08854-8020, fax 732/923-6926,bchavez{at}rci.rutgers.edu

OBJECTIVE: To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD).

DATA SOURCES: Searches of MEDLINE/PubMed (1992-February 2006) were conducted, as well as an extensive manual review of journals, using the key words autism and risperidone.

STUDY SELECTION AND DATA EXTRACTION: Only double-blind, placebo-controlled trials were included for review.

DATA SYNTHESIS: ASD is the most common of the pervasive developmental disorders. The main characteristics (core symptoms) of autism are impairment in social skills, problems communicating, and stereotypical movements. Behavioral manifestations or maladaptive behaviors include aggression, irritability, hyperactivity, inattention, impulsivity, tantrums, and self-injurious behavior.

CONCLUSIONS: Based on the data examined, risperidone appears efficacious and safe for treating certain behavioral aspects of autism including irritability, aggression, hyperactivity, and stereotypy. It does not appear to be as effective for the treatment of the core symptoms of autism.

Key Words: autism, pervasive developmental disorders, risperidone.

Published Online, March 7, 2006. www.theannals.com, DOI 10.1345/aph.1G389


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
J. M Stachnik and C. Nunn-Thompson
Use of Atypical Antipsychotics in the Treatment of Autistic Disorder
Ann. Pharmacother., April 1, 2007; 41(4): 626 - 634.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.